Comparative Effectiveness of Switching to Natalizumab or Fingolimod After Relapse on First-Line Relapsing-Remitting Multiple Sclerosis Therapy: Propensity Score Matching Analysis from the Msbase Registry.

AuthID
P-00P-V62
26
Author(s)
Harvrdova, EK
·
Horakova, D
·
Izquierdo, G
·
Kalincik, T
·
Lugaresi, A
·
Onofrj, M
·
Duquette, P
·
Girard, M
·
Prat, A
·
[+6]·
Sa, MJ
·
Terzi, M
·
Ozakbas, S
·
Van Pesch, V
·
Van Wijmeersch, B
·
Boz, C
·
Karabudak, R
·
Cartechini, E
·
McCombe, P
·
Butzkueven, H
1
Group Author(s)
MSBase Study Grp
Document Type
Abstract
Year published
2018
Published
in MULTIPLE SCLEROSIS JOURNAL, ISSN: 1352-4585
Volume: 24, Pages: 25-26 (2)
Conference
34Th Congress of the European-Committee-For-Treatment-And-Research-In-Multiple-Sclerosis (Ectrims), Date: OCT 10-12, 2018, Location: Berlin, GERMANY, Sponsors: European Comm Treatment & Res Multiple Sclerosis
Indexing
Publication Identifiers
Wos: WOS:000446861400033
Source Identifiers
ISSN: 1352-4585
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.
Name Order Name   Name Order Name   Name Order Name
1 Spelman, T;   2 Harvrdova, EK;   3 Horakova, D;
4 Izquierdo, G;   5 Kalincik, T;   6 Lugaresi, A;
7 Onofrj, M;   8 Duquette, P;   9 Girard, M;
10 Prat, A;   11 Grammond, P;   12 Grand'Maison, F;
13 Granella, F;   14 Lechner Scott, J;   15 Sola, P;
16 Ferrero, D;   17 Sa, MJ;   18 Terzi, M;
19 Ozakbas, S;   20 Van Pesch, V;   21 Van Wijmeersch, B;
22 Boz, C;   23 Karabudak, R;   24 Cartechini, E;
25 McCombe, P;   26 Butzkueven, H;